Pricing Log in Create free account

Silexion Therapeutics Corp (SLXN) vs VivoSim Labs, Inc. (VIVS)

Silexion Therapeutics Corp and VivoSim Labs, Inc. are both Biotechnology companies. Silexion Therapeutics Corp and VivoSim Labs, Inc. are of similar size ($2.8M and $2.7M). Silexion Therapeutics Corp has the higher net margin (0.00% vs −11,016.1%) and the higher return on invested capital (0.00% vs 0.00%). Across the 11 metrics below, Silexion Therapeutics Corp leads on 6 and VivoSim Labs, Inc. on 5.

Valuation

Metric SLXN VIVS Biotechnology median
P/E n/m n/m 8.50
P/S n/m 7.48 9.71
P/B 2.34 n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.04 0.07 0.64
EV/Sales n/m (7.42) 9.21
Earnings yield (14,489.87%) (2,793.75%) (33.15%)
Free cash flow yield (12,070.84%) (143.87%) (25.50%)

Profitability

Metric SLXN VIVS Biotechnology median
Gross margin — 100.00% 65.16%
Operating margin 0.00% (10,116.96%) 0.00%
Net margin 0.00% (11,016.07%) 0.00%
Free cash flow margin 0.00% (1,014.29%) 0.00%
Return on equity (17,021.95%) (343.10%) (56.36%)
Return on assets (277.96%) (155.93%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric SLXN VIVS Biotechnology median
Revenue growth (TTM) — (21.13%) 6.02%
EPS growth (last fiscal year) 97.73% (214.71%) 30.26%
Revenue growth, 5-year CAGR — (43.10%) 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric SLXN VIVS Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 0.94 1.70 4.72
Net debt to EBITDA 0.38 0.45 0.96

Dividend

Metric SLXN VIVS Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric SLXN VIVS Biotechnology median
Market cap 2.73m 2.84m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack